NCT02298348 2025-02-17
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01561833 2020-08-13
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Yale University
Phase 1 Completed
NCT02530476 2020-03-31
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02867280 2020-02-11
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University
Phase 3 Terminated
NCT01683149 2016-03-04
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00747799 2013-12-10
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2 Completed
NCT00536575 2013-02-27
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01262482 2012-11-09
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed